期刊文献+

精氨酸血管升压素受体拮抗剂临床应用研究进展 被引量:1

在线阅读 下载PDF
导出
摘要 精氨酸血管升压素(arginine vasopressin,AVP)是垂体后叶分泌的一种多肽类激素,具有多种生理作用。AVP最重要的作用是抗利尿,因此也称为抗利尿激素(antidiuretic hormone,ADH)。AVP不仅在维持渗透压稳态及血压调节中具有重要的作用,还参与一些病理生理过程。同其他激素一样,AVP的生理作用也由其受体介导。近年通过对AVP受体的深入研究,开发出一些化学物质,
作者 刘继红 苏青
出处 《中国临床药学杂志》 CAS 2008年第5期316-320,共5页 Chinese Journal of Clinical Pharmacy
  • 相关文献

参考文献25

  • 1Macion-Dazard R, Callahan N, Xu Z, et al. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor [J]. J Pharmacol Exp Ther,2006,316(2) :564.
  • 2Stemmelin J, l,ukovic L, Salome N, el al. Evidence that the lateral septurn is involved in the antidepressant-like effects of the vasopressin Vlb receptor antagonist, SSR149415[J]. Neuropsychopharmacology, 2005, 30( 1 ) :35.
  • 3lijima M, Chaki S. An arginine vasopressin Vlb antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2007,31 (3) : 622.
  • 4Siragy HM. Hyponatremia, fluidelectrolyte disorders, and the syndrome of inappropriate antidiuretic hormone secretion: diagnosis and treatment options[J]. Endocr Pract,2006,12(4) :446.
  • 5Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone[ J]. Am J Meal, 2006,119(Suppl 1 ) : S47.
  • 6Goldsmith SR. The role of vasopressin in congestive heart failure[ J]. Cleve Clin J Med, 2006,73 ( Suppl 3 ) : SI 9.
  • 7Wada K, Matsukawa U, Fujimori A, et al. A novel vasopressin dual VIA/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremla in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) [ J ]. Biol Pharm Bull, 2007,30( 1 ) : 91.
  • 8Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemie hyponatremia[J]. J Clin Endccrinol Metab,2006,91 (6):2145.
  • 9Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl j Med 2006,355:2099.
  • 10Hiroyama M, Wang S, Aoyagl T, et al. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice[J]. Eur J Phannacol,2007,559(2 - 3):89.

同被引文献13

  • 1Schrier RW,Gross P,Gheorghiade M,et al.?Tolvaptan,a selective oral vasopressin V2-receptor antagonist,for hyponatremia.New England Journal of Medicine.2006,355(20):2099-2112.
  • 2Abraham WT,Shamshirsaz AA,Mcfann K,et al.Aquaretic effect of lixivaptan,an oral,non-peptide,selective V2 receptor vasopressin antagonist,in New York Heart Association functional class II and III chronic heart failure patients.J Am Coll Cardiol.2006,47(8):1615-1621.
  • 3Potts MB,Degiacomo AF,Deragopian L,et al.Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.Neurosurgery.2011,69(2):268-273.
  • 4World Anti-Doping Agency:The 2014 Prohibited List.http://www.wada-ama.org.
  • 5Pei Q,Zhang BK,Tan HY,et al.Development and validation of an LC-MS/MS method for the determination of tolvaptan in huaman plasma and its application to a pharmacokitic study.J Chromatogr B,2013,913-914:84-89.
  • 6Derangula VR,Pillinr,Bhukya BR,et al.Bioanalysis of tolvaptan,a novel AVP-V2 receptor antagonist in human plasma by a novel LC-ESI-MS/MS method:a pharmacokinetic application in healthy south Indian male subject.Biomed Chromatogr,2014,28(3):332-340.
  • 7World Anti-Doping Agency:WADA Technical Document.http://www.wada-ama.org.
  • 8秦旸,徐友宣,杨树民,朱绍棠.液相色谱-质谱联用在兴奋剂检测中的应用及进展[J].色谱,2008,26(4):431-436. 被引量:9
  • 9向慧玲.肝硬化低钠血症与Vaptans[J].世界华人消化杂志,2010,18(12):1244-1249. 被引量:9
  • 10安丽媛,洪宇,徐友宣.人体毛发中类固醇类兴奋剂的液相色谱串联质谱检测方法研究[J].中国运动医学杂志,2014,33(6):576-582. 被引量:4

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部